Acadian Asset Management LLC Increases Holdings in Zoetis Inc. $ZTS

Acadian Asset Management LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 12.8% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 110,407 shares of the company’s stock after purchasing an additional 12,542 shares during the quarter. Acadian Asset Management LLC’s holdings in Zoetis were worth $18,174,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Zoetis by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after buying an additional 189,287 shares in the last quarter. Polen Capital Management LLC increased its stake in Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Northern Trust Corp increased its stake in Zoetis by 1.2% in the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after purchasing an additional 78,508 shares during the period. Goldman Sachs Group Inc. increased its stake in Zoetis by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock worth $847,293,000 after purchasing an additional 109,791 shares during the period. Finally, Brown Advisory Inc. increased its stake in Zoetis by 7.6% in the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock worth $725,866,000 after purchasing an additional 312,746 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.8%

NYSE ZTS opened at $150.66 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The firm has a market capitalization of $66.77 billion, a PE ratio of 25.93, a P/E/G ratio of 2.40 and a beta of 0.89. The stock’s 50 day moving average is $152.53 and its 200 day moving average is $157.45.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period in the previous year, the company posted $1.56 earnings per share. The firm’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ZTS shares. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Argus reaffirmed a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday. Piper Sandler lifted their price target on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.